LAUSR

About LAUSR
Donate
Contact Us

Follow us:

You are not signed in:

Sign Up!


   Articles with "dose atg" as a keyword



Photo from wikipedia

Combination of Haploidentical Hematopoietic with Low-Dose ATG, Ptcy and Cord Blood Competitive Transplantation for Hematologic Malignancies

Sign Up to like & get
recommendations! Published in 2019 at "Blood"

DOI: 10.1182/blood-2019-127624

Abstract: Objective: To evaluate the efficacy and safety of the combination of haploidentical hematopoietic with low-dose ATG, PTCy and cord blood competitive transplantation for hematologic malignancies. Methods: This study was conducted as a retrospective review of… read more here.

Keywords: low dose; blood; dose atg; cord blood ... See more keywords
Photo by towfiqu999999 from unsplash

Low-Dose ATG/GCSF in Established Type 1 Diabetes: A Five-Year Follow-up Report

Sign Up to like & get
recommendations! Published in 2021 at "Diabetes"

DOI: 10.2337/db20-1103

Abstract: Previously, we demonstrated low-dose antithymocyte globulin (ATG) and granulocyte colony-stimulating factor (GCSF) immunotherapy preserved C-peptide for 2 years in a pilot study of patients with established type 1 diabetes (n = 25). Here, we evaluated… read more here.

Keywords: low dose; dose atg; atg gcsf; type diabetes ... See more keywords
Photo by towfiqu999999 from unsplash

Low-Dose Anti-Thymocyte Globulin (ATG) Preserves β-Cell Function and Improves HbA1c in New-Onset Type 1 Diabetes

Sign Up to like & get
recommendations! Published in 2018 at "Diabetes Care"

DOI: 10.2337/dc18-0494

Abstract: OBJECTIVE A pilot study suggested that combination therapy with low-dose anti-thymocyte globulin (ATG) and pegylated granulocyte colony-stimulating factor (GCSF) preserves C-peptide in established type 1 diabetes (T1D) (duration 4 months to 2 years). We hypothesized… read more here.

Keywords: low dose; dose atg; dose anti; atg ... See more keywords

Lower dose of ATG combined with basiliximab for haploidentical hematopoietic stem cell transplantation is associated with effective control of GVHD and less CMV viremia

Sign Up to like & get
recommendations! Published in 2022 at "Frontiers in Immunology"

DOI: 10.3389/fimmu.2022.1017850

Abstract: Currently, the graft-versus-host disease (GVHD) prophylaxis consists of an immunosuppressive therapy mainly based on antithymocyte globulin (ATG) or post-transplant cyclophosphamide (PTCy). GVHD remains a major complication and limitation to successful allogeneic haploidentical hematopoietic stem cell… read more here.

Keywords: dose atg; gvhd prophylaxis; haploidentical hematopoietic; gvhd ... See more keywords